You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 2, 2025

Details for Patent: 6,251,368


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,251,368
Title: Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
Abstract:A pharmaceutical aerosol formulation which comprises particulate medicament selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant is disclosed. Also disclosed is a method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the, pharmaceutical aerosol formulation which may be contained in a canister.
Inventor(s): Akehurst; Rachel Ann (Ware, GB), Taylor; Anthony James (Ware, GB), Wyatt; David Andrew (Ware, GB)
Assignee: Glaxo Group Limited (Greenford, GB)
Application Number:08/877,198
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 6,251,368

Introduction

United States Patent 6,251,368, titled "Pharmaceutical Aerosol Formulation," is a patent that describes a specific formulation for pharmaceutical aerosols. To understand the scope and claims of this patent, it is essential to delve into its details, the patent landscape, and the broader context of pharmaceutical aerosol formulations.

Patent Overview

Title and Abstract

The patent, granted on June 26, 2001, is for a "Pharmaceutical Aerosol Formulation" that includes particulate medicaments such as Salmeterol, Salbutamol, and Fluticasone. The abstract outlines the composition and the method of preparing the aerosol formulation, emphasizing its stability and efficacy.

Background of the Invention

The background section of the patent discusses the need for stable and effective aerosol formulations for delivering medicaments directly to the lungs. It highlights the challenges associated with existing formulations, such as instability and poor delivery efficiency, and introduces the novel approach of the invention.

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically describe the essential features of the pharmaceutical aerosol formulation, including:

  • The type of particulate medicaments used (e.g., Salmeterol, Salbutamol, Fluticasone).
  • The composition of the formulation, including the presence of specific excipients and propellants.
  • The method of preparing the formulation to ensure stability and efficacy.

Dependent Claims

Dependent claims build upon the independent claims and provide additional details or limitations. These claims may specify particular ratios of ingredients, specific methods of manufacture, or additional components that enhance the formulation's performance.

Scope of the Invention

Patent Scope Measurements

The scope of a patent is crucial in determining its breadth and the extent to which it covers related inventions. According to the USPTO's Patent Claims Research Dataset, patent scope can be measured through various metrics, including claim-level statistics and document-level statistics. For Patent 6,251,368, the scope would be defined by the specific claims and the detailed description of the formulation and its preparation method[3].

Technological Field

This patent falls under the pharmaceutical and medical technology field, specifically within the category of respiratory treatments. The World Intellectual Property Organization (WIPO) classification system, which includes 35 technical fields, would categorize this patent under the field related to pharmaceuticals and medical preparations[4].

Patent Landscape

Global Patent Trends

In the context of global patent trends, pharmaceutical patents, including those for aerosol formulations, are significant indicators of innovation in the healthcare sector. The USPTO awarded a substantial number of utility patents in the pharmaceutical and medical fields in recent years, with a notable increase in patents related to respiratory treatments[4].

Competing Patents and Prior Art

To understand the competitive landscape, it is essential to search for prior art and competing patents. Tools like the USPTO's Patent Public Search, Global Dossier, and the Common Citation Document (CCD) can help identify related patents and citations from other IP offices. For example, searching through the European Patent Office's esp@cenet or the World Intellectual Property Organization's PATENTSCOPE can reveal similar or overlapping patents[1].

International Patent Considerations

International Patent Offices

The global nature of pharmaceutical research and development means that similar patents may exist in other countries. Databases from international intellectual property offices, such as the European Patent Office (EPO), Japan Patent Office (JPO), and China National Intellectual Property Administration (CNIPA), should be consulted to ensure that the invention is novel and non-obvious on a global scale[1].

Machine Translations and Language Barriers

Access to machine translations, as provided by some international patent offices, can facilitate the search for prior art in languages other than English. This is particularly useful for identifying patents that may not have been translated or widely disseminated[1].

Practical Implications and Enforcement

Patent Enforcement and Litigation

The practical implications of holding a patent like 6,251,368 include the exclusive right to make, use, or sell the invention. However, enforcing this right can be complex and may involve litigation. The concept of a small claims patent court, as studied by the Administrative Conference of the United States (ACUS), could potentially simplify the process for smaller inventors and businesses[2].

Licensing and Collaboration

Patent holders may also choose to license their inventions to other companies, which can be a lucrative way to monetize the patent. This often involves negotiating agreements that ensure the licensed technology is used in compliance with the patent claims.

Key Takeaways

  • Patent Claims: The patent's claims define its scope and are crucial for determining its novelty and non-obviousness.
  • Technological Field: The patent falls within the pharmaceutical and medical technology field, specifically respiratory treatments.
  • Global Landscape: Searching international patent databases is essential to ensure the invention's global novelty.
  • Enforcement: Patent enforcement can be complex, but options like licensing and potential small claims courts can simplify the process.
  • Innovation Trends: The patent is part of a broader trend in pharmaceutical innovation, particularly in respiratory treatments.

FAQs

Q: What is the main subject of United States Patent 6,251,368? A: The main subject is a pharmaceutical aerosol formulation containing particulate medicaments such as Salmeterol, Salbutamol, and Fluticasone.

Q: How can one search for prior art related to this patent? A: One can use tools like the USPTO's Patent Public Search, Global Dossier, and international patent databases such as the EPO's esp@cenet and WIPO's PATENTSCOPE.

Q: What are the practical implications of holding this patent? A: Holding this patent grants the exclusive right to make, use, or sell the invention, and it can be enforced through litigation or licensed to other companies.

Q: How does this patent fit into global patent trends? A: It is part of the broader trend in pharmaceutical innovation, particularly in respiratory treatments, and aligns with the increasing number of patents in this field globally.

Q: What resources are available for searching and analyzing patent data? A: Resources include the USPTO's Patent Claims Research Dataset, the Patent Public Search tool, and databases from international intellectual property offices.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. ACUS - U.S. Patent Small Claims Court: https://www.acus.gov/research-projects/us-patent-small-claims-court
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. NSF - Invention: U.S. and Comparative Global Trends: https://ncses.nsf.gov/pubs/nsb20204/invention-u-s-and-comparative-global-trends

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,251,368

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,251,368

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9126378Dec 12, 1991
United Kingdom9126405Dec 12, 1991
United Kingdom9202522Feb 06, 1992

International Family Members for US Patent 6,251,368

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 402 ⤷  Subscribe
African Regional IP Organization (ARIPO) 9200461 ⤷  Subscribe
Austria 128350 ⤷  Subscribe
Austria 163539 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.